About AVT
Browse Articles
Customer Services


Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase

Jean-Michel Pawlotsky, Isabel Najera, Ira Jacobson

Corresponding author name: Jean-Michel Pawlotsky
Corresponding author e-mail: jean-michel.pawlotsky@hmn.aphp.fr

Citation: Antiviral Therapy 2012; 17:411-423
doi: 10.3851/IMP2088

Date accepted: 10 October 2011
Date published online: 08 March 2012


Mericitabine (RG7128), an orally administered prodrug of PSI-6130, is the most clinically advanced nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV. This review describes what has been learnt so far about the resistance profile of mericitabine. A serine to threonine substitution at position 282 (S282T) of the RdRp that reduces its replication capacity to approximately 15% of wild-type is the only variant that has been consistently generated in serial in vitro passage experiments. To date, no evidence of genotypic resistance to mericitabine has been detected by population or clonal sequence analysis in any baseline or on-treatment samples collected from >600 patients enrolled in Phase I/II trials of mericitabine administered as monotherapy, in combination with pegylated interferon/ribavirin, or in combination with the protease inhibitor, danoprevir, for 14 days in the proof-of-concept study of interferon-free therapy.


Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.